top of page
  • Completed

NCT01985126: Phase 2 - Dara in MM who had 3 prior lines inc. PI, Imid - or db. ref. MMY2002 (SIRIUS)

Updated: Mar 28, 2022

MMY2002 (SIRIUS) Study


An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD


The purpose of this study is to evaluate the efficacy and safety of 2 daratumumab treatment regimens in participants with multiple myeloma who have received at least 3 prior lines of therapy (including a proteasome inhibitor [PI] and immunomodulatory drug [IMiD]) or are double refractory to a PI and an IMiD.


Multiple Locations

International Study


ClinicalTrials.gov Identifier: NCT01985126


 
 

Publications:


Lancet Haematol. 2020 Jun;7


Blood. 2016 Aug 18


Lancet. 2016 Apr 9





Comments


Posts Archive
bottom of page